Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
Holding ACRS?
Track your performance easily
ACRS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.59 - $6.98
Previous Close$1.21
Volume29.43K
Average Volume (3M)733.48K
Market Cap
$85.97M
Enterprise Value-$24.77M
Total Cash (Recent Filing)$111.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Nov 06, 2024EPS Estimate
>-$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding71,344,557
10 Day Avg. Volume222,996
30 Day Avg. Volume733,476
Standard Deviation0.38
R-Squared0.00093
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)0.64
Price to Sales (P/S)2.61
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.77
Enterprise Value/Gross Profit-1.88
Enterprise Value/Ebitda0.39
Forecast
1Y Price Target
$2.00Price Target Upside65.98% Upside
Rating ConsensusHold
Number of Analyst Covering3
Aclaris Therapeutics News
PremiumPre-Earnings
Is ACRS a Buy, Before Earnings?PremiumCompany Announcements
Aclaris Therapeutics Secures Deal with OMERS for OLUMIANT RoyaltiesBulls Say, Bears Say
Bulls Say
Clinical TrialsAclaris has dosed the first patient in the Phase 2a open-label trial of ATI-2138 for the treatment of moderate-to-severe atopic dermatitis.
Funding And Financial HealthCurrent balance sheet strength should fund operations through 2027, depending upon its level of investment in remaining pipeline programs.
Strategic Financial MovesSale of royalty and milestone payment revenue stream increases capital resources, constituting an astute, efficient way to raise non-dilutive funding and potentially position Aclaris for the acquisition of a transformative asset in the future.
Bears Say
PartnershipFailure to establish a partnership to conduct further development of ATI-1777.
Patient SatisfactionLess than 25% of atopic dermatitis patients are completely satisfied with current standard of care.
Strategic ReviewA company-wide strategic review was initiated following disappointing clinical data from zunsemetinib in rheumatoid arthritis and hidradenitis suppurativa, where both studies failed to achieve primary and key secondary endpoints.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ACRS FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was $0.59 and its highest was $6.98 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Currently, no data Available
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on Aug 07, 2024. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.205 by $0.055.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is >-$0.01.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 71,344,560 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.205. Following the earnings report the stock price went down -2.459%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Among the largest hedge funds holding Aclaris Therapeutics’s share is Aisling Capital Management LP. It holds Aclaris Therapeutics’s shares valued at 478K.
---
Aclaris Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (65.98% Upside)
$2.00 (65.98% Upside)
Hedge Fund Trend
Decreased
By 13.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.64%
12-Months-Change
Fundamentals
Return on Equity
-37.43%
Trailing 12-Months
Asset Growth
-31.65%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
---
ACRS Company Deck
---
ACRS Earnings Call
Q1 2024
0:00 / 0:00
---
ACRS Stock 12 Month Forecast
Average Price Target
$2.00
▲(65.98% Upside)
Technical Analysis
Best Analysts Covering ACRS
1 Year
1 Year Success Rate
0/0 ratings generated profit
1 Year Average Return
0.00%
initiated a buy rating 12 months ago
Copying Unknown Analyst's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
---